Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
about
The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligandProtein associated with SMAD1 (PAWS1/FAM83G) is a substrate for type I bone morphogenetic protein receptors and modulates bone morphogenetic protein signallingGrowth factor signaling in lung morphogenetic centers: automaticity, stereotypy and symmetryAnti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologistFunctional redundancy of TGF-beta family type I receptors and receptor-Smads in mediating anti-Mullerian hormone-induced Mullerian duct regression in the mouse.Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta.Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting SubstanceInduction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression.AMH induces mesonephric cell migration in XX gonadsMullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma modelMullerian inhibiting substance acts as a motor neuron survival factor in vitro.Focal Mullerian duct retention in male mice with constitutively activated beta-catenin expression in the Mullerian duct mesenchymeMüllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumorsMullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.Anti-Müllerian hormone recruits BMPR-IA in immature granulosa cells.Regulation of gonadotropin gene expression by Mullerian inhibiting substance.Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancerc-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signalingCommon mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian CancerPartial Müllerian Duct Retention in Smad4 Conditional Mutant Male MiceMullerian inhibiting substance recruits ALK3 to regulate Leydig cell differentiation.Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells.Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.The TGF-β Family in the Reproductive Tract.Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads.Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.The type I BMP receptor ACVR1/ALK2 is required for chondrogenesis during development.Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.
P2860
Q24306670-6A697981-005A-4AB7-B84C-7F99F710FABFQ24337871-986ECBEB-79DD-480A-B98D-27CAADC15540Q24795748-6094C622-DF8F-476E-A97F-51BC1DC50F5AQ28661014-04112FA2-6115-45BC-B519-88EF96EFF77AQ33621021-7D4BFFD6-1CAC-475F-882C-2664C06A863AQ33637210-14381BCB-8103-4EFA-BDE0-16553B4AB45CQ33716008-EFE7E86C-1BCB-48F7-8E63-2F5458309842Q33719519-31E310B8-BDD9-41BE-ABA0-BADAF53BEB17Q33815479-4F5DC5AD-3261-4315-9780-3B8DDF340B3CQ33897273-ADFF16B3-30D3-44D3-AB14-FB4221368ADEQ33927553-43BB2AD4-5AD3-46B8-B1CB-DAB90FBD9CD4Q34132471-8ADC7519-F061-43E4-BA6A-F78407A786BDQ34136372-DF410F77-4AC2-474C-BD09-46BE9BD7E158Q34246272-BBAB3F18-6968-4ED2-A5D0-EA0CFA3226EDQ34434627-BF49427B-DC4A-4DA9-8CFC-6F9074B68813Q35060595-6FAFEE18-C626-4EBA-83A2-078C2D9BFD11Q35234562-CF3084B3-4383-4D9D-98BB-B9D04974D70BQ35768666-D8A44635-B650-43EB-B59B-D894BF863215Q35787316-92B7CF31-B28D-4EC3-94D9-6DEC51A19C2CQ35961381-225C7ACC-816D-43C9-B27E-45BB7A848CDDQ36372596-B2198FD8-1141-429C-9913-1FFA2A2EE275Q36435768-76BABF84-7AAD-4BDD-BBC1-3BFC4A124039Q36578816-D32F00BD-736F-46C0-8299-469E920B7A35Q36637142-281708D2-3D21-447F-ADB5-BF1FFDCFD291Q36743937-B763B18C-165B-4358-AE1B-73510E30BD64Q36911079-0222FF9F-D99B-4C77-A529-211D0A5EA15FQ36937954-499E7BED-BA2C-4E24-AC5C-83D23790BB8FQ37136953-D53F3217-ECF1-40C1-8BCA-AF3CFC3D7549Q37707380-0C18B230-0D9C-4711-9AB0-25F5A9E168C1Q38963328-5BFB5C25-0E4E-409A-AEC2-19680C93F0DEQ39791091-4FFD9D54-F432-4746-8280-9E156010B95CQ41903017-CB89DA1F-A0B1-47D6-9DDB-6491AA49C1A6Q42176868-3B3A2CA9-BA2D-4384-9311-94423F731984Q53459641-B5093C3F-ECDF-4543-85C0-5EC6B3FE70A0
P2860
Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Müllerian inhibiting substance ...... and induces SMAD6 expression.
@en
type
label
Müllerian inhibiting substance ...... and induces SMAD6 expression.
@en
prefLabel
Müllerian inhibiting substance ...... and induces SMAD6 expression.
@en
P2093
P356
P1476
Müllerian inhibiting substance ...... and induces SMAD6 expression.
@en
P2093
P304
P356
10.1210/MEND.15.6.0664
P577
2001-06-01T00:00:00Z